Vijay Kumar Kuchroo
Director/Board Member bei SYNGENE INTERNATIONAL LIMITED
Profil
Vijay Kumar Kuchroo is the founder of Celsius Therapeutics, Inc. founded in 2018.
He is currently the Director at Massachusetts Institute of Technology, Director at Evergrande Centre For Immunologic Diseases, Co-Director-Infection & Immunity at Brigham Research Institute, and a Professor at Harvard Medical School.
He is also a Member of The Broad Institute, Inc. and a Member of the Scientific Advisory Board at Potenza Therapeutics, Inc. Additionally, he is an Independent Non-Executive Director at Syngene International Ltd.
since 2017.
He was previously an Independent Non-Executive Director at Biocon Ltd.
from 2015 to 2023 and a Senior Scientist at The Brigham & Women's Hospital, Inc. He received his doctorate degree from The University of Queensland.
Dr. Kuchroo is also the founder of CoStim Pharmaceuticals, Inc., Tempero Pharmaceuticals, Inc., Tizona Therapeutics, Inc., and Larkspur Biosciences, Inc.
Aktive Positionen von Vijay Kumar Kuchroo
| Unternehmen | Position | Beginn |
|---|---|---|
| SYNGENE INTERNATIONAL LIMITED | Director/Board Member | 01.03.2017 |
| Harvard Medical School | Corporate Officer/Principal | - |
| Evergrande Centre For Immunologic Diseases | Director/Board Member | - |
Potenza Therapeutics, Inc.
 Potenza Therapeutics, Inc. BiotechnologyHealth Technology Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Celsius Therapeutics, Inc.
 Celsius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA. | Founder | 01.01.2018 |
| Brigham Research Institute | Corporate Officer/Principal | - |
| Massachusetts Institute of Technology | Director/Board Member | - |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Director/Board Member | - |
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Ehemalige bekannte Positionen von Vijay Kumar Kuchroo
| Unternehmen | Position | Ende |
|---|---|---|
| ░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░ ░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
Ausbildung von Vijay Kumar Kuchroo
| The University of Queensland | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIOCON LIMITED | Health Technology |
| SYNGENE INTERNATIONAL LIMITED | Commercial Services |
| Private Unternehmen | 11 |
|---|---|
Potenza Therapeutics, Inc.
Potenza Therapeutics, Inc. BiotechnologyHealth Technology Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA. | Health Technology |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
CoStim Pharmaceuticals, Inc.
 CoStim Pharmaceuticals, Inc. BiotechnologyHealth Technology CoStim Pharmaceuticals, Inc. operates as a biotech company which develops biologics for oncology indications. It offers therapies which target immune checkpoint inhibitors for novel treatment. The company was founded on February 01, 2013 and is headquartered in Boston, MA. | Health Technology |
| Tempero Pharmaceuticals, Inc. | Commercial Services |
| Evergrande Centre For Immunologic Diseases | |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
Celsius Therapeutics, Inc.
Celsius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA. | Health Technology |
| Brigham Research Institute | |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Health Technology |
Larkspur Biosciences, Inc.
 Larkspur Biosciences, Inc. BiotechnologyHealth Technology Larkspur Biosciences, Inc. is a company based in Watertown, MA that is pioneering a new wave in cancer therapy. Larkspur’s approach targets cancer-intrinsic factors that tumors use to escape immune detection and control to develop new treatment options for patients who cannot be helped by current therapies. The company is advancing first-in-class programs designed to eliminate tumor “bottlenecks” that drive immune evasion in colorectal cancer (CRC) and beyond. Larkx, the company’s proprietary bioinformatics platform, couples machine learning with tumor genetics to discover immune evasion pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. The company was founded by Nathanael S. Gray, Vijay Kumar Kuchroo, and Lewis Clayton Cantley. The CEO is Catherine Sabatos-Peyton. | Health Technology |
